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Visceralobesityandfattyliverhavebeenrelatedtohighsynthesisandlowabsorptionofcholesterol.Thisstudyaimedtoinvestigate
the associations of cholesterol metabolism with liver and visceral fat content in healthy humans. Another objective was to explore
the eﬀects of very-high-fructose and very-high-glucose diets on cholesterol homeostasis. We report on a cohort of 20 people (12
males, 8 females; age 30.5 ± 2.0 years; body mass index 25.9 ± 0.5kg/m 2) who completed a four-week dietary intervention study.
Between the baseline and the followup examination the study participants in addition to a balanced weight-maintaining diet
received 150g of either fructose or glucose per day. Visceral and liver fat were measured with magnetic resonance (MR) imaging
and 1H-MR spectroscopy, respectively. Cholesterol absorption and synthesis were estimated from the serum noncholesterol sterol
concentrations. Performing cross-sectional analyses the lanosterol and desmosterol to cholesterol ratios were positively correlated
with visceral and liver fat content (all P<. 03). The lathosterol to cholesterol ratio decreased in response to high-fructose diet
(P = .006) but not in response to high-glucose diet. To conclude, visceral and liver fat content are associated with cholesterol
synthesis in healthy humans. Furthermore, cholesterol synthesis appears to be dependent on fructose/glucose intake.
1.Introduction
Serum cholesterol is either derived from intestinal absorp-
tion or from endogenous synthesis [1]. The individual
balance of cholesterol absorption and synthesis is highly
heritable [2]. The ATP-binding cassette transporters G5 and
G8 (ABCG5/8) and the Niemann-Pick C1 Like1 protein
(NPC1L1) play important roles in cholesterol homeostasis.
Both genes encode proteins that are expressed in the intes-
tine and regulate cholesterol absorption [3–5]. However,
cholesterolabsorptionandsynthesisarenotonlydetermined
by genetic factors but also by the metabolic state [6–10].
For example, subjects with high body mass index display
high synthesis and low absorption of cholesterol [6–8].
Furthermore, cholesterol synthesis prevails over cholesterol
absorption in insulin resistance and type 2 diabetes [7–
11]. In agreement, visceral obesity is associated with a high
synthesis phenotype [12, 13]. Recently, fatty liver, which is
thought to be involved in the pathogenesis of the metabolic
syndrome [14–17], was also found to be associated with high
cholesterol synthesis and low cholesterol absorption [18].
The present work aimed to investigate whether visceral
and liver fat contents are correlated with cholesterol home-
ostasis in healthy humans. Our hypothesis was that even
modest diﬀerences of liver and visceral fat content would be
reﬂected by diﬀerences in cholesterol synthesis and absorp-
tion. To answer this question, we performed cross-sectional
analyses in 20 healthy individuals who participated in a2 Experimental Diabetes Research
four-week dietary intervention (either very-high-fructose or
very-high-glucose diet) study [19]. Another objective of this
study was to investigate the impact of very-high-fructose
intake, which has been found to alter lipid metabolism [20–
23], on cholesterol homeostasis.
Visceral and liver fat contents were measured with mag-
netic resonance (MR) imaging and 1H-MR spectroscopy,
respectively. To estimate cholesterol absorption and synthe-
sis, we measured the serum concentrations of lathosterol,
lanosterol, desmosterol (cholesterol precursors, indicate
endogenous cholesterol synthesis), campesterol, sitosterol
(plant sterols, indicate intestinal cholesterol uptake), and
cholestanol (5-α saturated derivative of cholesterol indicates
intestinal cholesterol uptake) [24–26].
2. Methods
2.1. Study Design and Diet. We report on an exploratory,
prospective, randomized, single-blinded, outpatient, inter-
vention study (TUbingen FRuctose Or Glucose study) [19].
Inclusion criteria were age 20–50 years, body mass index
20–35kg/m2, physical health, and not more than one-
hour sports per week. Exclusion criteria were pregnancy,
any relevant illness, fructose intolerance, medication, metal
implants, regular alcohol consumption ≥10g/day, and claus-
trophobia. The participants received 150g (600kcal) of
e i t h e rf r u c t o s eo rg l u c o s ep e rd a yf o rf o u rw e e k s .T h e yw e r e
blinded to the type of intervention. The sugar was provided
in identical plastic packs of 50g and had to be dissolved
in water (50g sugar in 250mL water). The participants
were instructed to consume the sugar in addition to a
balanced weight-maintaining diet (50% carbohydrates, 35%
fat, and 15% protein). Fructose or glucose was ingested
three times a day (morning, midday, evening) with the
main meals. Dietary counseling was provided by a trained
dietitian according to the guidelines of the German Society
of Nutrition. We aimed to assess compliance with the dietary
prescription by close telephone contact. The participants
were instructed to immediately inform the investigators in
case of problems with the intake of fructose or glucose. For
that,theywereprovidedacallingcard.Furthermore,compli-
ance was evaluated by interview at visits 1 and 2. In addition,
the subjects were asked to ﬁll out food intake records on 3
days in each week of the study which were controlled and
evaluated by a trained dietician using DGE PC software.
Blood sampling, oral glucose tolerance testing, magnetic
resonance imaging, and magnetic resonance spectroscopy
were performed before and after dietary intervention. The
study was approved by the local ethics committee and was
conducted in accordance with the “Declaration of Helsinki.”
Informedwrittenconsentwasobtainedfromallparticipants.
Data from the 20 participants who completed the study were
included in the present analyses [19].
2.2. Laboratory Analyses. Total, HDL, and LDL cholesterol
concentrations were measured with a standard colorimetric
method on a Bayer analyzer (Bayer Health Care, Lev-
erkusen, Germany). The serum noncholesterol sterols
were measured using gas-liquid chromatography—mass
spectrometry—selected ion monitoring (Hewlett Packard
5890) with an automatic injection system (Hewlett Packard
Automatic Sampler 7673A) as previously described [27].
Blood glucose was de-termined using a bedside glucose
analyzer based on a glucose-oxidase method (Yellow Springs
Instruments, Yellow Springs, Colo). Insulin was analyzed by
microparticle enzyme immunoassay (Abbott Laboratories,
Tokyo, Japan).
2.3. Oral Glucose Tolerance Test. We performed standard
75g oral gluose tolerance tests after a 10-h overnight fast.
Venous plasma samples were obtained at 0, 30, 60, 90, and
120min for determination of plasma glucose and insulin.
InsulinsensitivitywasestimatedfromtheOGTTasproposed
by Matsuda and DeFronzo: ISIest = 10,000/
√
(Insmean ×
Glucmean ×Ins0 × Gluc0)[ 28].
2.4. Quantitative Analysis of Visceral and Liver Fat. Visceral
fat mass was measured with an axial T1-weighed fast spin
echo technique with a 1.5T whole-body imager (Magne-
tom Sonata; Siemens Medical Solutions) in the complete
abdominal region, ranging from head of femur to head of
humerus [29]. Liver fat was determined by localized proton
magnetic resonance spectroscopy applying a single-voxel
STEAM technique with short echo time (TE) as previously
described [30, 31].
2.5. Statistical Analysis. The clinical and biochemical char-
acteristics are presented as numbers and percentages and
means ± standard errors of the means for categorical and
continuous data, respectively. Ratios of the noncholesterol
sterols to cholesterol (measured with gas-liquid chromatog-
raphy) were calculated (see Table 2) .T h eu n i v a r i a t er e l a -
tionships of the noncholesterol sterols with cholesterol, the
relationships among the noncholesterol sterol to cholesterol
ratios, and the relationships of the cholesterol subfractions
and the noncholesterol sterol ratios with fat depots and
insulin sensitivity were analyzed with linear regression
models. The results are shown as Pearson correlation coef-
ﬁcients. Furthermore, we performed multivariate analysis
for the associations of the cholesterol subfractions and the
noncholesterolsteroltocholesterolratioswithfatdepotsand
insulin sensitivity using Analysis of Covariance (ANCOVA).
Alterations in the noncholesterol sterol to cholesterol ratios
inresponsetofructoseandglucoseinterventionwerestudied
with the paired samples t-test (two-sided tests). ANCOVA
was used to compare the changes in the noncholesterol sterol
to cholesterol ratios (e.g., change in lathosterol to cholesterol
ratio between baseline and followup examination) between
the fructose and glucose intervention groups, with study
group as the main factor and the metabolic parameter
of interest at baseline (e.g., lathosterol to cholesterol ratio
at baseline examination) as covariate (two-sided tests). To
estimate the treatment eﬀect, diﬀerences in least-square
means and the corresponding 95% conﬁdence intervals were
calculated based on the ANCOVA models [32]. Data that
were not normally distributed (Shapiro-Wilk W test) wereExperimental Diabetes Research 3
Table 1: Baseline characteristics of the study participants.
Baseline examination
Males/females, n 12/8
Age, years 30.5 ± 2.0
Body mass index, kg/m2 25.9 ± 0.5
Waist, cm 85 ± 2
Visceral fat, kg 2.2 ± 0.2
Liver fat, % signal 1.5 ± 0.2
Systolic blood pressure, mmHg 117 ± 3
Diastolic blood pressure, mmHg 77 ± 2
Total cholesterol, mg/dL 175 ± 5
LDL cholesterol, mg/dL 106 ± 5
HDL cholesterol, mg/dL 54 ± 2
VLDL cholesterol, mg/dL 15 ± 2
Non-HDL cholesterol, mg/dL 122 ± 5
Fasting glucose, mmol/L 4.86 ± 0.06
Fasting insulin, pmol/L 48 ± 7
Insulin sensitivity Matsuda,
arbitrary units 17.6 ± 2.1
Values are numbers and percentages and means with standard errors of the
means for categorical and continuous data, respectively.
Table 2: Serum levels of the noncholesterol sterol to cholesterol
ratios at baseline.
Lathosterol/cholesterol, μg/mg 1.28 ± 0.11
Desmosterol/cholesterol, μg/mg 0.49 ± 0.02
Lanosterol/cholesterol, μg/mg 0.31 ± 0.02
Campesterol/cholesterol, μg/mg 1.58 ± 0.11
Sitosterol/cholesterol, μg/mg 1.22 ± 0.09
Cholestanol/cholesterol, μg/mg 1.72 ± 0.06
Values are means with standard errors of the means.
transformed logarithmically (base-10). P values <0.05 were
considered signiﬁcant. The JMP statistical software package
7.0 (SAS Institute, Cary, NC, USA) was used.
3. Results
The baseline characteristics of the study participants are
shown in Table 1.T h em e a n± standard error of the mean
serum concentrations were 186 ± 5mg/dL for cholesterol
(GCMS), 0.241 ± 0.024mg/dL for lathosterol, 0.091 ±
0.006mg/dL for desmosterol, 0.058 ± 0.004mg/dL for
lanosterol, 0.295 ± 0.023mg/dL for campesterol, 0.229 ±
0.018mg/dL for sitosterol, and 0.320 ± 0.014mg/dL for
cholestanol.
T h es e r u md e s m o s t e r o la n dc h o l e s t a n o ll e v e l sw e r es i g -
niﬁcantly related to cholesterol (r = 0.631, P = .002 and
r = 0.615, P = .004, resp.). The lathosterol, desmosterol,
and lanosterol to cholesterol ratios were also positively
correlated (Table 3). In agreement, the ratios of campesterol
and sitosterol to cholesterol showed a signiﬁcant positive
association (Table 3). Furthermore, the ratio of campesterol
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Figure 1: The associations of (a) visceral and (b) liver fat with the
lanosterol to cholesterol ratio adjusted for sex, age, and body mass
index.
to cholesterol was signiﬁcantly related to the ratio of
cholestanol to cholesterol (Table 3). The ratio of lathosterol
tocholesterolwasinverselyrelatedtotheratioofcampesterol
to cholesterol (Table 3).
High lanosterol and desmosterol to cholesterol ratios
were signiﬁcantly associated with increased visceral and liver
fat content (Table 4). The association of the lanosterol to
cholesterol ratio with visceral (P = .033) and liver fat
(P = .044) was independent of sex, age, and body mass
index (Figure 1). The cholesterol absorption markers were
not signiﬁcantly related to visceral and liver fat (Table 4).
HDL cholesterol was inversely related to visceral fat and
liver fat content whereas non-HDL cholesterol was positively
correlated with visceral fat (Table 4). LDL cholesterol was
not associated with fat depots (Table 4). The lathosterol to
cholesterol ratio was inversely related to insulin sensitivity
(Table 4).
The lathosterol to cholesterol ratio signiﬁcantly de-
creased in response to very-high-fructose diet but not in4 Experimental Diabetes Research
Table 3: Univariate correlations among the noncholesterol sterol to cholesterol ratios.
Lathosterol/
cholesterol
Desmosterol/
cholesterol
Lanosterol/
cholesterol
Campesterol/
cholesterol
Sitosterol/
cholesterol
Cholestanol/
cholesterol
Lathosterol/cholesterol — 0.572† 0.489‡ −0.493‡ −0.378 −0.378
Desmosterol/cholesterol 0.572† — 0.607† −0.280 −0.173 −0.357
Lanosterol/cholesterol 0.489‡ 0.607† — −0.059 0.000 −0.036
Campesterol/cholesterol −0.493‡ −0.280 −0.059 — 0.880∗ 0.486‡
Sitosterol/cholesterol −0.378 −0.173 0.000 0.880∗ — 0.375
Cholestanol/cholesterol −0.378 −0.357 −0.036 0.486‡ 0.375 —
Values are Pearson correlation coeﬃcients calculated with linear regression; ∗P < 0.001, †P<0.01, ‡P<0.05.
Table 4: Univariate correlations of total cholesterol, cholesterol subfractions, and the noncholesterol sterol to cholesterol ratios with liver
fat, visceral fat, and insulin sensitivity.
Liver fat Visceral fat Insulin sensitivity
rPrPr P
Total cholesterol 0.194 0.384 0.243 0.303 0.082 0.730
LDL cholesterol 0.386 0.145 0.363 0.116 −0.049 0.839
HDL cholesterol −0.545 0.011 −0.593 0.006 0.045 0.852
VLDL cholesterol 0.035 0.884 0.254 0.279 0.280 0.231
Non-HDL cholesterol 0.386 0.093 0.452 0.046 0.066 0.783
Lathosterol/cholesterol 0.107 0.636 0.404 0.078 −0.500 0.025
Desmosterol/cholesterol 0.548 0.027 0.541 0.014 −0.259 0.271
Lanosterol/cholesterol 0.642 0.004 0.629 0.003 −0.364 0.114
Campesterol/cholesterol −0.005 0.710 −0.253 0.282 0.335 0.149
Sitosterol/cholesterol 0.040 0.803 −0.279 0.234 0.200 0.397
Cholestanol/cholesterol 0.008 0.974 0.060 0.800 0.325 0.163
r Pearson correlation coeﬃcients and P values calculated with linear regression (liver fat was transformed logarithmically for calculation of the P values).
response to very-high-glucose diet with the diﬀerence
between interventions reaching statistical signiﬁcance
(Table 5). In agreement, there was a signiﬁcant treatment
eﬀect for the alterations of the lanosterol to cholesterol ratio
(Table 5). No changes or treatment eﬀects were found for the
desmosterol to cholesterol ratio and the absorption marker
to cholesterol ratios (Table 5).
4. Discussion
We found that the ratios of desmosterol and lanosterol to
cholesterol,whichindicateendogenouscholesterolsynthesis,
were positively associated with visceral and liver fat content
in persons at relatively low metabolic risk. The relationships
of the lanosterol to cholesterol ratio with visceral and liver
fat were independent of obesity. Furthermore, high ratio of
lathosterol to cholesterol, also an indicator of cholesterol
synthesis, was related to lower insulin sensitivity.
O u ro b s e r v a t i o n sﬁ tw e l li nt h ec o n t e x to ft h ep r e v i o u s l y
published studies in the ﬁeld. High body mass index, insulin
resistance, and type 2 diabetes have been independently
associated with high cholesterol synthesis [6–11]. Visceral
obesity and just recently fatty liver were also related to
increased synthesis of cholesterol [12, 13, 18]. Our study
extends these ﬁndings in the sense that we report on a cohort
of healthy people. Furthermore, we have also measured the
cholesterol synthesis marker lanosterol which was obviously
thenoncholesterolsterolmoststronglyrelatedtovisceraland
liver fat content. We did not ﬁnd signiﬁcant associations of
cholesterol absorption with visceral or liver fat. This may
suggest that fat distribution and ectopic fat deposition in the
liver primarily aﬀect cholesterol synthesis. In this respect,
it seems noteworthy that visceral fat was not signiﬁcantly
related to the sitosterol to cholesterol ratio in a recent study
either [13].
Why is liver fat content positively correlated with choles-
terol synthesis? The most important regulator of cellular
cholesterol synthesis is the sterol regulatory element-binding
protein2(SREBP2),amembrane-boundtranscriptionfactor
[33, 34]. This transcription factor is highly expressed in the
liver and interestingly, its activity is increased in subjects
with high liver fat [35]. However, the exact mechanisms
accountingfortheactivationofSREBP2insubjectswithhigh
liver fat seem poorly understood.
Since cholesterol homeostasis is obviously associated
with liver fat content, the following question arises: might
pharmacological interventions targeting cholesterol home-
ostasis have an impact on hepatic lipid content? A well-
performed study by Szendroedi et al. found that even high-
dose simvastatin treatment has no direct eﬀects on liver fatExperimental Diabetes Research 5
Table 5: Changes in the noncholesterol sterol to cholesterol ratios in response to high-fructose or high-glucose diet.
Fructose intervention group Glucose intervention group Fructose versus glucose
Baseline Change P∗ Baseline Change P∗ ΔLSM 95% CI P†
Lathosterol/cholesterol, μg/mg 1.16 ± 0.11 −0.20 ± 0.06 0.006 1.40 ± 0.20 −0.08 ± 0.18 0.659 −0.28 −0.53 to −0.04 0.027
Desmosterol/cholesterol, μg/mg 0.45 ± 0.03 0.01 ± 0.02 0.675 0.52 ± 0.04 −0.02 ± 0.04 0.638 −0.01 −0.08 to 0.07 0.809
Lanosterol/cholesterol, μg/mg 0.30 ± 0.03 −0.03 ± 0.03 0.332 0.32 ± 0.02 0.03 ± 0.04 0.555 −0.08 −0.16 to 0.00 0.040
Campesterol/cholesterol, μg/mg 1.74 ± 0.13 −0.07 ± 0.07 0.337 1.42 ± 0.17 0.05 ± 0.15 0.746 −0.10 −0.47 to 0.27 0.569
Sitosterol/cholesterol, μg/mg 1.28 ± 0.09 −0.07 ± 0.05 0.165 1.16 ± 0.15 0.01 ± 0.09 0.889 −0.06 −0.26 to 0.14 0.562
Cholestanol/cholesterol, μg/mg 1.82 ± 0.06 −0.10 ± 0.10 0.348 1.61 ± 0.09 −0.07 ± 0.06 0.307 −0.04 −0.32 to 0.25 0.796
Values are means ± standard errors of the means; change: absolute diﬀerence between visits 1 and 2; fructose versus glucose: treatment eﬀect of fructose
intervention compared to glucose intervention; ΔLSM: diﬀerence in least squares means between fructose and glucose intervention (calculated with Analysis
of Covariance with correction for baseline values); CI: conﬁdence interval; ∗P value for change between visits 1 and 2 calculated with paired samples t-test
(two-sided); †P value for diﬀerence in change between fructose and glucose intervention (calculated with Analysis of Covariance with correction for baseline
values, two-sided).
content in people with type 2 diabetes [36]. In contrast,
the cholesterol absorption inhibitor ezetimibe was found
to increase the reduction of liver fat in obese subjects on
a weight-loss diet [37]. Whether the use of plant sterols
and stanols, which similarly act as inhibitors of cholesterol
absorption [38], will help to reduce hepatic steatosis remains
to be investigated.
Wealsostudiedtheeﬀectsofveryhigh-fructoseandvery-
high-glucose diets on cholesterol absorption and synthesis.
High-fructosediethasbeenimplicatedinthepathogenesisof
the metabolic syndrome, fatty liver, and type 2 diabetes [20–
23]. Moreover, a recent study suggested that high-fructose
diet was associated with increased plasma concentrations of
LDL cholesterol, small dense LDL, and oxidized LDL [23].
Theeﬀectofhigh-fructosedietoncholesterolhomostasishas
not been investigated so far. According to the present ﬁnd-
ings, fructose compared with glucose appears to less strongly
stimulate cholesterol synthesis. This novel observation may
be explained by the fact that fructose does not provoke
endogenous secretion of insulin [20] ,w h i c hi sc o n s i d e r e d
to be an important regulator of cholesterol synthesis [39].
Alternatively, the treatment eﬀect for cholesterol synthesis
may result from the signiﬁcant weight gain in the glucose
intervention group (+1.7kg) which was not observed in the
fructose intervention group (+0.2kg) [19].
Consistent with earlier work [12, 13, 40, 41], the serum
HDL cholesterol concentration was signiﬁcantly decreased
in subjects with high visceral and liver fat content in the
presentcohort.Hence,increasedvisceralandliverfatcontent
mayindicateearlydisturbanceoflipidmetabolisminhealthy
people. It is also in agreement with a recent trial that
the serum total and LDL cholesterol concentrations were
not signiﬁcantly related to visceral and liver fat content in
our cohort of healthy individuals [12]. Hoenig et al. even
showedthatlow-densitylipoproteincholesterolwasinversely
correlated with the abdominal visceral fat area in subjects
with established vascular disease [13]. The authors discussed
that their ﬁnding could explain the loss of the relationship
between LDL cholesterol and cardiovascular events in the
obese and support the use of non-HDL cholesterol instead
of LDL cholesterol as the primary therapeutic target for lipid
lowering therapy [13, 42]. Our data may support this view
considering that we observed a positive correlation of non-
HDL cholesterol with visceral fat.
Finally, our data conﬁrm that intestinal cholesterol
absorption and endogenous cholesterol synthesis are interre-
lated considering the signiﬁcant inverse association between
the ratios of lathosterol and campesterol to cholesterol [7,
24].
The sample size of our study is relatively low. We
cannot, therefore, rule out that a signiﬁcant association of
visceral and liver fat content with the cholesterol absorption
markers could be observed in a larger cohort of healthy
individuals. To compensate for this drawback, we used very
precise and stringently validated analytical procedures for
the quantiﬁcation of the noncholesterol sterols and the fat
depots. The serum concentrations of the noncholesterol
sterols were measured using a highly sensitive and speciﬁc
gas-liquid chromatography method. Visceral and liver fat
content were quantiﬁed using magnetic resonance imaging
and magnetic resonance spectroscopy, respectively. We also
want to highlight that the sample size of our cohort
was similar or even larger compared with previous highly
recognized studies fructose intervention studies [21].
In conclusion, we found an independent association
of visceral and liver fat content with cholesterol synthesis
in healthy humans. Moreover, we were able to show for
the ﬁrst time that cholesterol synthesis is dependent on
fructose/glucose intake. Studies investigating whether
marked alterations of liver fat content will have an impact
on cholesterol homeostasis are encouraged.
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